NKG2A & CD94

NKG2A & CD94 詳細

英語名NK cell lectin-like receptor subfamily C member 1市販薬剤の数0
治験薬の数6ターゲットの別称CD159a,NKG2A,KLRC1,Killer Cell Lectin Like Receptor C1,Killer Cell Lectin-Like Receptor Subfamily C, Member 1,CD159 Antigen-Like Family Member A,NKG2-1/B Activating NK Receptor,NKG2-A/B-Activating NK Receptor,NK Cell Receptor A,NKG2-A/NKG2-B Type II Integral Membrane Protein,NKG2-A/B Type II Integral Membrane Protein,Natural Killer Group Protein 2,Natural Killer Cell Lectin,C-Lectin Type II Protein,CD159a Antigen,NKG2,NKG2-B,NKG2-A
研究&開発段階Phase 3 Clinical
英語名NK cell lectin-like receptor subfamily C member 1
ターゲットの別称CD159a,NKG2A,KLRC1,Killer Cell Lectin Like Receptor C1,Killer Cell Lectin-Like Receptor Subfamily C, Member 1,CD159 Antigen-Like Family Member A,NKG2-1/B Activating NK Receptor,NKG2-A/B-Activating NK Receptor,NK Cell Receptor A,NKG2-A/NKG2-B Type II Integral Membrane Protein,NKG2-A/B Type II Integral Membrane Protein,Natural Killer Group Protein 2,Natural Killer Cell Lectin,C-Lectin Type II Protein,CD159a Antigen,NKG2,NKG2-B,NKG2-A
市販薬剤の数0
治験薬の数6
研究&開発段階Phase 3 Clinical

NKG2A & CD94 製品リスト

  • 属性

    Protein (10)

  • 製品ライブラリ

    オンライン (10)

  • Human (5)Cynomolgus (2)Mouse (3)

  • タグ

    Mouse IgG Fc Tag (1)Fc Tag & Avi Tag (3)His Tag (3)Fc Tag (2)His Tag & Avi Tag (1)

  • マーカー

    Unconjugated (6)Biotin-labeled (4)

NKG2A & CD94バックグランド

CD94 plays a role as a receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells. KLRD1 (CD94) is an antigen preferentially expressed on NK cells and is classified as a type II membrane protein because it has an external C terminus. NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation. CD94 pairs with the NKG2 molecule as a heterodimer. The CD94/NKG2 complex, on the surface of natural killer cells interacts with Human Leukocyte Antigen (HLA)-E on target cells.

NKG2A & CD94分子の別称

NKG2A & CD94

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
MonalizumabNNC-0141-0000-0100; NNC 0141-0000-0100; IPH-22XX; IPH-22; NN-8765; IPH-2201Phase 3 ClinicalNovo Nordisk A/SArthritis, Rheumatoid; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Genital Neoplasms, Female; Head and Neck Neoplasms; Hematologic Neoplasms; Inflammation; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Oral Squamous Cell Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms
詳細
BMS-986315BMS-986315Phase 2 ClinicalBristol-Myers Squibb CompanyCarcinoma, Non-Small-Cell Lung; Solid tumours
詳細
S-095029S-095029Phase 2 ClinicalInstitut De Recherches Internationales ServierCarcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Solid tumours; Stomach Neoplasms
詳細
HY000102HY-0102; HY-000102Phase 2 ClinicalShanghai HyaMab Biotech Co LtdPancreatic Neoplasms; Solid tumours
詳細
XB-628XB628Phase 1 ClinicalExelixis IncNeoplasms; Solid tumours
詳細
BRY-805BRY805; BRY-805Phase 1 ClinicalHisun Biopharmaceutical Co Ltd, Zhejiang BioRay Biopharmaceuticals Co LtdSolid tumours
詳細
  • 詳細
  • 製品リスト
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8